CAMP4 Therapeutics Corporation(CAMP)

Biotechnology · Cambridge, MA

$3.90-0.11 (-2.74%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T14:11:13.311Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:11:13.311Z.

Quote observation: 2026-10-06T14:10:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 244,737,480
Total debt · period ending 2026-06-30: 2,372,000
Cash · period ending 2026-06-30: 87,128,000
TTM operating income · period ending 2026-06-30: -52,384,000

FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CAMP EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CAMP Competitors' EV/EBIT Ratio

CAMP

CAMP4 Therapeutics Corporation

Current

Market Cap

$244.74M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GALT

Galectin Therapeutics Inc.

vs CAMP

Market Cap

$239.06M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BDSX

Biodesix, Inc.

vs CAMP

Market Cap

$240.50M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HITI

High Tide Inc.

vs CAMP

Market Cap

$240.76M

EV/EBIT Ratio

100.49x

TTM Avg

177.33x

3Y Avg

172.45x

5Y Avg

172.45x

GLSI

Greenwich LifeSciences, Inc.

vs CAMP

Market Cap

$243.66M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFCR

Lifecore Biomedical, Inc.

vs CAMP

Market Cap

$243.81M

EV/EBIT Ratio

N/A

TTM Avg

98.16x

3Y Avg

1055.07x

5Y Avg

378.93x

IFRX

InflaRx N.V.

vs CAMP

Market Cap

$241.56M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKBA

Akebia Therapeutics, Inc.

vs CAMP

Market Cap

$236.90M

EV/EBIT Ratio

N/A

TTM Avg

245.87x

3Y Avg

245.87x

5Y Avg

245.87x

BIOA

BioAge Labs Inc.

vs CAMP

Market Cap

$234.93M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGNX

MacroGenics, Inc.

vs CAMP

Market Cap

$234.38M

EV/EBIT Ratio

N/A

TTM Avg

378.61x

3Y Avg

334476.42x

5Y Avg

334476.42x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
CAMP4 Therapeutics Corporation (CAMP)	$244.74M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$239.06M	N/A	N/A	N/A	N/A
Biodesix, Inc. (BDSX)vs ›	$240.50M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$240.76M	100.49x	177.33x	172.45x	172.45x
Greenwich LifeSciences, Inc. (GLSI)vs ›	$243.66M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$243.81M	N/A	98.16x	1055.07x	378.93x
InflaRx N.V. (IFRX)vs ›	$241.56M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$236.90M	N/A	245.87x	245.87x	245.87x
BioAge Labs Inc. (BIOA)vs ›	$234.93M	N/A	N/A	N/A	N/A
MacroGenics, Inc. (MGNX)vs ›	$234.38M	N/A	378.61x	334476.42x	334476.42x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

CAMP EV/EBIT Ratio Metrics

CAMP Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics